Lumen Bioscience—a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases—today announced new development funding from the US Army for its Covid-19 monoclonal antibody drug cocktail. The support is provided by the US Army Medical Research and Development Command (USAMRDC), operating through the Medical Technology Enterprise Consortium (MTEC).